Evidence map›Paper›PMID 31902327›Full record

ArticleJournal of the American Heart Association2020

Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.

Abhinav Sharma, Muthiah Vaduganathan, João Pedro Ferreira, Yuyin Liu, George L Bakris, Christopher P Cannon, William B White, Faiez Zannad

Open access · goldAbstract readEquivalence TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Abhinav SharmaINSERM CIC 1433 NI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network Université de Lorraine and CHRU Nancy France.
Muthiah VaduganathanBrigham and Women's Hospital Heart and Vascular Center Harvard Medical School Boston MA.
João Pedro FerreiraINSERM CIC 1433 NI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network Université de Lorraine and CHRU Nancy France.
Yuyin LiuBaim Institute for Clinical Research Boston MA.
George L BakrisUniversity of Chicago Medicine Chicago IL.
Christopher P CannonBaim Institute for Clinical Research Boston MA.
William B WhiteUniversity of Connecticut School of Medicine Farmington CT.
Faiez ZannadINSERM CIC 1433 NI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network Université de Lorraine and CHRU Nancy France.
Baim Institute for Clinical Research · USUniversité de Lorraine · FRBrigham and Women's Hospital · USMcGill University · CAUniversity of Chicago · USUniversity of Connecticut · US

Funding

The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
NCATS NIH HHS UL1 TR002541
6 · The paper itself

Abstract

Background Improved heart failure (HF) risk stratification after a recent acute coronary syndrome may identify those who can benefit from therapies that reduce HF risk. We aimed to identify clinical and biomarker predictors for expanded HF outcomes in patients with type 2 diabetes mellitus after recent acute coronary syndrome. Methods and Results The EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial was a multicenter, non-inferiority, double-masked, placebo-controlled study which randomized 5380 patients with type 2 diabetes mellitus after recent acute coronary syndrome to alogliptin or placebo. Baseline biomarkers were measured in 5154 patients: NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity troponin I, adiponectin, growth-differentiation-factor-15, and galectin-3. Our primary outcome was cardiovascular) death, HF hospitalization, elevated NT-proBNP during follow-up, or loop diuretics initiation. The association between clinical variables, biomarkers, and outcomes were assessed using Cox regression models. In the study population, the median age was 61.0 years, 67.7% were men, and 28.0% had baseline HF (median follow-up was 18 months). In multivariable analyses, NT-proBNP had the strongest association with the primary outcome (per log

Indexed as

Acute Coronary SyndromeAgedBiomarkersBlood ProteinsDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDouble-Blind MethodFemaleGalectin 3GalectinsGrowth Differentiation Factor 15Heart Disease Risk FactorsHeart FailureHospitalizationHumansMalealogliptinBiomarkersBlood ProteinsDipeptidyl-Peptidase IV InhibitorsGalectin 3GalectinsGDF15 protein, humanGrowth Differentiation Factor 15LGALS3 protein, humanNatriuretic Peptide, BrainPeptide FragmentsPiperidinespro-brain natriuretic peptide (1-76)Troponin IUracilbiomarkersheart failurenatriuretic peptiderisk stratification

Identifiers

PMID31902327
PMCPMC6988143
OpenAlexW2996957335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.